Abstract
In an updated analysis from the phase III MONALEESA‐3 trial with more than 4.5 years of follow‐up, ribociclib plus fulvestrant maintained a significant overall survival benefit compared with fulvestrant alone in postmenopausal women with HR‐negative, HER2‐positive advanced breast cancer.